Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.73 is 49% below its 4-year average of -1.16, near the low end of its 4-year range (-2.17–0.13).
8.95% above its 12-month average of -1.90.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.40.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 10 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T12:46:10.372Z. Historical observations retain their original dates. Historical series through 2024-08-14.
EARNINGS PER SHARE (EPS)
-1.73
EARNINGS PER SHARE (EPS) AVG TTM
-1.90
EARNINGS PER SHARE (EPS) AVG 3Y
-1.16
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+8.95%
CURRENT VS 3Y AVG
-49.14%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Contineum Therapeutics, Inc.
Market Cap
$478.54M
Earnings Per Share (EPS)
-1.73
TTM Avg
-1.90
3Y Avg
-1.16
5Y Avg
N/A
Market Cap
$481.33M
Earnings Per Share (EPS)
0.16
TTM Avg
-2.02
3Y Avg
-3.99
5Y Avg
-3.80
Market Cap
$471.57M
Earnings Per Share (EPS)
-0.04
TTM Avg
-0.10
3Y Avg
-0.16
5Y Avg
-0.22
Market Cap
$487.30M
Earnings Per Share (EPS)
-1.99
TTM Avg
-0.88
3Y Avg
-1.91
5Y Avg
-1.95
Market Cap
$491.55M
Earnings Per Share (EPS)
-1.98
TTM Avg
-3.65
3Y Avg
-4.15
5Y Avg
-2.79
Market Cap
$491.93M
Earnings Per Share (EPS)
-0.52
TTM Avg
-0.81
3Y Avg
-1.01
5Y Avg
-1.63
Market Cap
$453.70M
Earnings Per Share (EPS)
-0.72
TTM Avg
-0.65
3Y Avg
-0.60
5Y Avg
-0.64
Market Cap
$450.64M
Earnings Per Share (EPS)
0.55
TTM Avg
-3.62
3Y Avg
-10.86
5Y Avg
-15.74
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | $478.54M | -1.73 | -1.90 | -1.16 | N/A |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 0.16 | -2.02 | -3.99 | -3.80 |
| Cerus Corporation (CERS)vs › | $471.57M | -0.04 | -0.10 | -0.16 | -0.22 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | -1.99 | -0.88 | -1.91 | -1.95 |
| NRC Health (NRC)vs › | $468.31M | 0.25 | 0.79 | 1.03 | 1.18 |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -1.98 | -3.65 | -4.15 | -2.79 |
| Evolus, Inc. (EOLS)vs › | $491.93M | -0.52 | -0.81 | -1.01 | -1.63 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | -0.72 | -0.65 | -0.60 | -0.64 |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | 0.55 | -3.62 | -10.86 | -15.74 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | -2.45 | -1.70 | -1.35 | -1.20 |
Trailing EPS (TTM)
$-1.73
Forward EPS (Est.)
$-1.72
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.17 |
| 2024-12-31 | -1.63 |
| 2023-12-31 | 0.13 |
| 2022-12-31 | -0.97 |
| 2021-12-31 | -1.15 |
